In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tamiflu, Vioxx Pediatric Adverse Event Reports To Be Presented At Committee Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Pediatric Advisory Committee will also hear pediatric adverse event reports on Agrylin, Paraplatin, Diflucan, Camptosar, Ferrlecit and Imitrex at Nov. 18 meeting.

You may also be interested in...

Roche Increases Tamiflu Manufacturing Capacity In Time For 2006 Season

President Bush will request $7.1 bil. for pandemic avian flu preparedness, $1 bil. of which will be earmarked for antiviral stockpiling.

Shire/Noven Methypatch For ADHD To Be Reviewed By Psychopharm Committee

Companies seek indication for once-daily methylphenidate patch for the treatment of attention deficit/hyperactivity disorder in children ages six to 12 years.

J&J Concerta, Methylphenidate Adverse Events Not New Signal, Committee Says

FDA's pediatric committee is hesitant to recommend a labeling change for attention deficit/hyperactivity disorder drugs based on current data. FDA should, however, communicate concerns about psychiatric events to the public, possibly through Drug Watch website.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts